2026-03-09T18:20:35Z https://hirosaki.repo.nii.ac.jp/oai

oai:hirosaki.repo.nii.ac.jp:00003726 2023-05-15T09:46:56Z 557:1754615242943:561:648

<Case Study>Enhancement of Warfarin Anticoagulant Activity by S-1 <症例研究>S-1によるワーファリン抗凝固作用の増強 ショウレイ ケンキュウ S-1 ニヨル ワーファリン コウギョウコ サヨウ ノ ゾウキョウ Terui, Kazufumi Takahata, Takenori Sato, Junya Ishiguro, Atsushi Itoh, Jugoh Hayakari, Makoto Saijo, Yasuo 492.3 内科系臨床医学 coagulation S-1 warfarin 相互作用 ワーファリン S-1, an oral prodrug of 5-fluorouracil, has been employed in treatment of solid tumors in Japan. We report two patient cases whose international normalized ratio（INR）increased due to concomitant treatment with warfarin and S-1. In case 1, a 63-year-old man, who had taken 3.5 mg/day warfarin for dilated cardiomyopathy, had a subcutaneous hematoma in a left lower eyelid on the ninth course of combination chemotherapy with S-1 and docetaxel for metastatic gastric cancer. His INR increased to 3.68 despite careful monitoring of coagulation parameters. In case 2, a 68-year-old man, who received combination chemotherapy with S-1 and irinotecan for metastatic colorectal cancer, had to reduce the dose of warfarin twice during the same chemotherapy courses because of repeated prolongation of INR. We speculate that multiple mechanisms of unstable INR are involved in strengthening the anticoagulant effect of warfarin. Frequent monitoring of INR is required to prevent unexpected adverse events of coagulation abnormality induced by the interaction between S-1 and warfarin． 弘前医学. 62(1), 2011, p.80-85 弘前大学出版会 2011-03-15 eng journal article VoR http://hdl.handle.net/10129/4425 https://hirosaki.repo.nii.ac.jp/records/3726 AN00211444 0439-1721 弘前医学 62 1 80 85 https://hirosaki.repo.nii.ac.jp/record/3726/files/HirosakiMedJ_62(1)_80.pdf application/pdf 860.8 kB 2018-03-13